Dacomitinib-d10
Dacomitinib-d10 (PF-00299804-d10; PF-299804-d10) is the deuterated-labeled Dacomitinib (HY-13272). Dacomitinib (PF-00299804; PF-299804) is an orally active irreversible pan-ERBB receptor tyrosine kinase inhibitor with inhibitory activity against HER1/EGFR, HER2, and HER4. Dacomitinib exerts antitumor effects in various tumor cells, inhibiting tumor cell proliferation, migration, and invasion, inducing cell cycle arrest and apoptosis, regulating the expression of molecules related to the cell cycle, apoptosis, and epithelial-mesenchymal transition, and it can also reverse partial drug resistance, producing synergistic effects when combined with chemotherapy. Dacomitinib inhibits key signaling pathways such as PI3K‑AKT‑mTOR and PLK1‑FOXM1. Dacomitinib ameliorates pathological changes associated with pulmonary arterial hypertension in rats. Dacomitinib can be used in research on breast cancer, bladder cancer, epithelial ovarian cancer, and pulmonary arterial hypertension.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Fòrmula: C24H15D10ClFN5O2
- Peso molecular:480.00
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
Ver todos los productos específicos de isoformas EGFR
MoreVer todos los productos específicos de isoformas Caspase
More
Actividad biológica
Descripciòn
|
CDK1 |
CDK2 |
Caspase-3 |
Caspase-7 |
Akt |
ERK |
EGFR |
HER1 6 nM (IC50) |
HER2 45.7 nM (IC50) |
HER4 73.7 nM (IC50) |
Aplicación
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
Unlabeled CAS 1110813-31-4
-
Peso molecular 480.00
-
Fòrmula C24H15D10ClFN5O2
-
SMILES
COC(C(NC(/C=C/CN1C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C1([2H])[2H])=O)=C2)=CC3=C2C(NC4=CC(Cl)=C(C=C4)F)=NC=N3
-
Synonyms
PF-00299804-d10; PF-299804-d10
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
[4]. Shirley M, et al. Dacomitinib: First Global Approval. Drugs. 2018 Dec;78(18):1947-1953.
[5]. Kalous O, et al. Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib. Molecular cancer therapeutics. 2012 Sep;11(9):1978-87. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Dacomitinib-d10 Related Classifications
HY-13272S3 Related Classifications
Powered by Bioz
Keywords
- Dacomitinib-d10
- PF-00299804-d10
- PF-299804-d10
- Isotope-Labeled Compounds
- EGFR
- IAP
- Akt
- ERK
- PI3K
- Survivin
- Caspase
- CDK
- Apoptosis
- HER2-amplified breast cancer
- pulmonary arterial hypertension
- AsPC-1
- pancreatic ductal adenocarcinoma
- epithelial ovarian cancer
- PaTu 8902
- pan-ERBB receptor tyrosine kinase inhibitor
- PANC-1
- non-small cell lung cancer
- bladder cancer
- Inhibitor
- inhibitor
- inhibit